It is now clear that the mast cell's functional response to IgE-dependent stimulation can be influenced significantly by the level of expression of the high-affinity IgE receptor (FcεRI) on the cell's surface. Thus, modulation of FcεRI surface expression represents a potentially important mechanism for regulating mast cell activity in allergic reactions. In this study, we examined whether a glucocorticoid, dexamethasone (DEX), can influence levels of mast cell FcεRI expression either in the presence or absence of IgE, an up-regulator of the mast cell surface FcεRI level. In the absence of IgE, DEX decreased the surface FcεRI levels in mouse peritoneal mast cells, mouse bone marrow-derived cultured mast cells and a mouse mast cell line, Cl.MC/C57.1. Moreover, DEX also partially suppressed the ability of IgE to enhance surface expression of FcεRI in these cells. Three different glucocorticoids, DEX, methylprednisolone and hydrocortisone, suppressed FcεRI expression in mast cells, whereas sex steroids, i.e. estradiol, progesterone and testosterone, did not, indicating that the FcεRI-suppressing effect is glucocorticoid specific. On the other hand, DEX did not affect levels of FcεRI α, β or γ mRNA, suggesting that its ability to decrease surface FcεRI reflects a post-transcriptional mechanism. Finally, DEX-treated mast cells showed a reduced degranulation response to antigenic stimulation through down-regulation of surface FcεRI expression in addition to DEX-induced changes in downstream signals. These results show that mast cell surface FcεRI expression is suppressed by glucocorticoids in both the presence and absence of IgE, and suggest that reduction of mast cell surface FcεRI levels may be one of the favorable anti-allergic actions of glucocorticoids.
Introduction
IgE-mediated stimulation of mast cells and basophils is an levels of FcεRI on the surface of mast cells and basophils can be regulated by extracellular factors (5) (6) (7) (8) (9) (10) . For example, important initial event in type I allergic reactions. The highaffinity receptor for IgE (FcεRI) is abundantly expressed on we (6, 7, 11, 12) and others (10,13) have already reported that IgE can potently enhance mast cell surface FcεRI expression, these cells and following stimulation via FcεRI, mast cells and basophils release bioactive chemical mediators such as and the up-regulation of surface FcεRI levels is functionally important because mast cells with a high level of FcεRI histamine, resulting in the initiation of allergic reactions (1, 2) . FcεRI is required for mast cells to initiate IgE-mediated allergic on their surface show enhanced sensitivity and a stronger response to antigenic stimulation. reactions, because mice deficient in FcεRIα fail to exhibit allergic reactions even in the presence of antigen and antigenIn accord with advances in our understanding of the mechanisms which can up-regulate mast cell and basophil specific IgE (3, 4) . Several lines of evidence have shown that surface FcεRI levels in vitro and in vivo, increasing considera-DMEM supplemented with 10% FCS, L-glutamine and tion is being given to therapeutic approaches that can 2-mercaptoethanol. influence levels of expression of FcεRI. Recombinant humanized anti-IgE antibody (E25) was recently reported to have Flow cytometric analysis benefit in patients with allergic asthma (14, 15) . In parallel with Flow cytometric analysis of mast cells was performed essena striking reduction in free IgE (Ͻ5% of initial levels), which tially as reported previously (6, 7) . In brief, mouse peritoneal includes IgE recognizing allergen-specific epitopes (14, 15) . mast cell preparations were preincubated for 15 min with Administration of E25 also resulted in both reduced expression 2.4G2 mAb (PharMingen, San Diego, CA) at 10 µg/ml to of basophil FcεRI expression and diminished skin sensitivity block the low-affinity binding of IgE to FcγRII/III. Cells were to allergen challenge (9) . Because E25 antibody does not then incubated at 4°C with mouse monoclonal IgE (SPE-7; react with FcεRI-bound IgE on the surface of mast cells and Sigma, St Louis, MO) at 10 µg/ml for 50 min and then for the basophils, the decrease in cell surface FcεRI levels probably last 25 min with a biotinylated rat anti-mouse c-kit antibody does not reflect any direct action of E25 on FcεRI ϩ cells, but (PharMingen) at 15 µg/ml. After washing, the cells were indirect consequences of the decreased concentrations of stained with FITC-rat anti-mouse IgE antibody (PharMingen) serum IgE (9, 16 Mouse FcεRI α, β and γ chain cDNAs were obtained as cell factor (SCF) at 50 ng/ml (PeproTech, London, UK), 50 µM reported previously (22, 23) . Plasmids containing their cDNA 2-mercaptoethanol and antibiotics (penicillin/streptomycin) were amplified in Escherichia coli and then extracted using (Gibco). Mast cells comprised~3-5% of the total peritoneal a Maxiprep isolation kit followed by enzyme digestion. cells as assessed by May-Grü nwald-Giemsa stain. Before 32 P-labeled probes were produced using a Rediprime II DNA analysis of changes in the mast cell surface FcεRI level, cells labeling system (Amersham Pharmacia Biotech, Tokyo, were cultured for indicated times with or without a steroid Japan). and/or mouse ascites IgE (5 µg/ml).
Northern blot hybridization was done in a QuikHyb HybridBone marrow-derived cultured mast cells (BMCMC), Ͼ99%
ization Solution (Toyobo, Tokyo, Japan) overnight at 65°C and purity, were generated by culturing femoral bone marrow cells blots were washed under stringent conditions. The hybridized of BALB/c mice (SLC, Shizuoka, Japan) in 20% WEHI-3 cell blots were then exposed to an imaging plate (BAS SR; supernatant-conditioned DMEM supplemented with 10% FCS, Fuji Photo Film, Tokyo, Japan), and radioactive bands were L-glutamine, 2-mercaptoethanol and antibiotics for 5-6 weeks.
visualized and measured using FUJIX Bas 2500 (Fuji Photo Cloned mast cells, Cl.MC/C57.1 (C57) cells, originally derived from a BALB/c mouse (20,21) were maintained in Film).
For both types of mast cells, statistically significant inhibition was observed when DEX at 10 or 100 nM was included in the culture medium (Figs 1 and 2A). Importantly, suppression of the surface FcεRI level by DEX was observed in peritoneal mast cells and BMCMC even in the presence of IgE, indicating that incubation with IgE does not abolish the down-regulating effect of DEX on mast cell FcεRI levels. The effect of DEX was time dependent: an apparent decrease in the FcεRI level was observed after as short as 6 h of culture of BMCMC, in either the presence or absence of IgE (Fig. 2B) . In order to examine whether DEX can actively suppress levels of IgE-bound FcεRI, BMCMC were cultured with IgE at 5 µg/ml for 4 day, which is a sufficient period for full induction of surface FcεRI, before treatment of the cells with DEX. As shown in Fig. 3 , the maximal level of surface FcεRI expression on BMCMC, obtained after 4-day culture with IgE at 5 µg/ml, was significantly reduced by the treatment with DEX for 20 h, indicating that DEX treatment can enhance the disappearance of IgE-bound FcεRI from the cell surface.
It should to be noted that the effects of DEX on levels of effect on Fc receptor expression, because treatment of BMCMC with DEX at 100 nM, which decreased the level of FcεRI (Fig. 4A ), had no effect on surface expression of FcγRII/ III (Fig. 4B) .
Activation of mast cells

C57 cells were cultured for 20 h with or without mouse ascites
Glucocorticoids, but not sex steroids, can reduce mast cell IgE at 5 µg/ml and/or DEX at 100 nM. The cells were then surface FcεRI expression incubated with IgE at 5 µg/ml for 2 h on ice to fully saturate
In the next series of experiments, we investigated the effects their surface FcεRI, washed with PIPES buffer containing of various steroids on mast cell surface FcεRI levels. The 0.1% BSA, and then resuspended in PIPES buffer containing mouse mast cell line, C57 cells, were cultured with or without 1 mM Ca 2ϩ and 0.4 mM Mg 2ϩ . The cells were stimulated with IgE (at 5 µg/ml) and/or one of various steroids (at 100 nM) either DNP-HSA (Sigma) or ionophore A23187 (Sigma) for for 16 h, and their FcεRI expression was analyzed by flow 45 min at 37°C and histamine released into the supernatant cytometry. As shown in Fig. 5(A) , glucocorticoids, including was measured using an automated fluorimeter as described DEX, hydrocortisone and methylprednisolone, reduced mast by Siraganian (24). The percentage of histamine release was cell FcεRI expression, while sex steroids, i.e. estradiol, progescalculated by the following formula: 100ϫ(released histamterone and testosterone, failed to affect the surface level of ine -spontaneous release)/(total histamine -spontaneous FcεRI. Importantly, the level of surface FcεRI expression was release). Spontaneous histamine release did not exceed 7% also partially suppressed by the glucocorticoids, but not by of the total histamine content.
the sex steroids (Fig. 5B) , when we tested mast cells that were undergoing increases in levels of FcεRI in the presence Statistics of IgE (at 5 µg/ml). Unless otherwise specified, all data were expressed as the mean Ϯ SEM and all differences between values were comAnalysis of FcεRI α, β and γ mRNA levels in mast cells pared by the two-tailed Student's t-test (unpaired).
cultured with DEX
To examine whether DEX might influence FcεRI expression at the transcriptional level, we assessed the mRNA levels of Results each subunit of FcεRI by Northern blot hybridization. However, DEX can suppress levels of mast cell surface FcεRI we observed no obvious differences in the mRNA levels for expression the FcεRI α, β and γ chains in C57 cells cultured with or without IgE (at 5 µg/ml) and/or DEX (at 100 nM), even though We analyzed the effect of DEX on FcεRI expression using mast cells cultured in both the absence and presence of IgE.
a DEX-induced decrease in the surface FcεRI level was clearly detected by flow cytometric analysis (Fig. 6 ). Because As shown in Figs 1 and 2 , DEX suppressed the level of surface FcεRI expression on mouse peritoneal mast cells treatment with DEX resulted in a modest decrease (by~40%) in mRNA levels of β-actin without affecting RNA recovery from (Fig. 1) and BMCMC (Fig. 2) in a dose-dependent fashion. compared with the corresponding ratio of 0 h sample in Fig. 6 ) 0.7-1.0 for DEX-treated cells) further suggest that DEX does not influence mRNA levels of any of the FcεRI α, β or γ chains. We also performed RT-PCR analysis of BMCMC cultured with or without IgE and/or DEX, but again, no apparent decreased levels of FcεRI expression due to exposure to DEX demonstrated reduced histamine release, whether or not the differences in the density of amplified bands for the FcεRI α, β and γ chains were found (data not shown). These results cells had also been cultured for 20 h in the presence of IgE (Fig. 7) . Compared with mast cells that had not been treated suggest that the effects of DEX on mast cell surface FcεRI levels were mediated by post-transcriptional regulation.
with DEX, DEX-treated cells showed suppressed histamine release on stimulation with a given concentration of antigen, DEX-treated mast cells with suppressed FcεRI levels exhibit in addition to decreased sensitivity to antigen stimulation; diminished IgE-dependent activation however, the percentage of histamine release caused by stimulation with A23187 was not changed by treatment of To assess whether the DEX-induced changes in mast cell FcεRI levels are associated with a functional change, we cells with DEX (Fig. 7) . Although DEX-treated mast cells showed suppressed hiscultured C57 cells for 20 h with or without IgE and/or DEX, and then stimulated the cells with specific antigen or a nontamine release compared with untreated mast cells, the effect of DEX may be due to the changes in either (or probably both) specific secretagogue (calcium ionophore A23187). In accord with our previous reports (6, 7, 11) mast cells with an increased surface FcεRI levels and/or intracellular signal transduction. In the last series of experiments, we examined whether the DEXlevel of surface FcεRI expression after culture with IgE demonstrated an enhanced histamine release reaction to FcεRI-induced decrease in surface FcεRI levels (by 30-50%) is functionally significant. Following treatment for 20 h with or dependent stimulation, although the percentage of release caused by non-specific stimulation with ionophore A23187 without DEX at 100 nM but without IgE, C57 mast cells were sensitized with IgE at 5 µg/ml on ice for various time periods, was virtually unchanged (Fig. 7) . In contrast, mast cells with cells' effector functions, such as the release of chemical mediators, thus reducing the severity of allergic inflammation at the sites of allergic diseases.
Several effects of glucocorticoids on mast cells have also been reported (17,18,30-32) including reduction in the numbers of tissue mast cells (33) , and suppression of IgE-and antigen-induced responses such as leukotriene release (18) and cytokine production (31) . In spite of these other antiallergic actions of glucocorticoids, glucocorticoid-induced modulation of mast cell FcεRI expression may be of particular importance because such effects theoretically can influence all FcεRI-mediated downstream events.
In this study, we have demonstrated that DEX not only can suppress the baseline levels of unoccupied FcεRI on mast cells, but also can result in reduction of the FcεRI levels in cells that have FcεRI occupied by IgE and have undergone IgE-dependent up-regulation of FcεRI expression. Although the regulation of mast cell surface FcεRI expression is not fully understood, studies using a mast cell line, i.e. rat basophilic leukemia (RBL) cells, showed that an important by IgE because DEX induces reductions in both IgE-occupied and -unoccupied FcεRI from the surface, whereas IgE of course stabilizes only IgE-occupied FcεRI (4). Recently, there has been considerable progress in research on the intracellui.e. 5, 20, 60 or 120 min, allowing various levels of saturation of surface FcεRI with IgE ( Fig. 8A-C) . When DEX-untreated lar mechanisms of corticosteroid action: corticosteroids, coupled with their receptors, suppress the transcription of cells with different densities of surface-bound IgE were stimulated, their degranulating response was affected by the levels various inflammatory molecules, whereas they enhance the transcription of other molecules possessing mainly antiof surface IgE (Fig. 8D) . Even the two DEX-untreated cell preparations with relatively small differences (by 35%) in inflammatory activities (36,37). However, the exact mechanism(s) responsible for the ability of DEX to down-regulate surface IgE levels (120 versus 60 min sensitization) showed a significantly different percentages of histamine release in levels of surface FcεRI remain(s) to be determined. The level of mast cell surface FcεRI expression clearly can response to antigenic stimulation, indicating that such a small change is functionally significant. DEX-treated cells showed influence the cell's functional response to FcεRI-dependent stimulation (6, 7, 11, 12) ; we found that this is also true in DEXsignificantly reduced degranulating response compared with DEX-untreated, correspondingly sensitized cells and the treated mast cells. Thus, the decrease in surface FcεRI level on C57 cells induced by treatment of the cells with DEX decrease in degranulation was especially obvious when cells were stimulated with low levels of antigen (DNP-HSA at 0.1 ng/ was accompanied by a significantly reduced degranulation response to antigenic stimulation. Although the consequences ml) (e.g. compare the two-cell preparations with almost the same levels of surface-bound IgE; DEX-untreated, 60-min of DEX action on mast cells may vary among different species and for the different biological functions of mast cells, the sensitized cells versus DEX-treated, 120-min sensitized cells). These results clearly show that the DEX-induced decrease in release of leukotrienes and proinflammatory cytokines from rodent mast cells in vitro is potently suppressed by corticosmast cell FcεRI levels is functionally significant and that DEX also affects mast cell degranulating response via other teroids (18,31). Previous work has suggested that the magnitude of corticosteroid effects on mast cell degranulation may intracellular mechanisms.
vary among mast cells of different phenotypes and even among different batches of mast cells of a single phenotype Discussion (30). However, our results consistently showed that pretreatment of C57 cells with DEX at 100 nM for 20 h significantly Glucocorticoids are recognized as very effective medications for various allergic diseases, including bronchial asthma, and reduced the histamine release response to antigen challenge, but not to non-IgE-mediated stimulation with calcium ionoit is widely accepted that allergic inflammation is potently suppressed by these agents. Glucocorticoids act not only on phore. Our findings are in line with the results reported by Robin et al. (18) and Benhamou et al. (17) , who showed that lymphocytes, but also on eosinophils (26), basophils (27) (28) (29) and other types of inflammatory cells, and can suppress the BMCMC treated for 24 h with DEX but without IgE demonstrated decrease in both surface FcεRI levels and surface FcεRI expression are one important point to be considered when devising therapeutic strategies for IgE-β-hexosaminidase release to IgE-dependent stimulation. In addition, we have found that the DEX-induced decrease in mediated allergic diseases. Anti-human IgE therapy is known to potently suppress the serum IgE concentration, resulting both surface FcεRI levels and IgE-mediated degranulation can also occur in IgE-containing situations. In both the in reduced basophil surface FcεRI levels (9, 14) . This antibody demonstrates not only clinical benefit in patients with allergic absence and presence of IgE during culture, the effect of DEX on mast cell degranulation was even more pronounced asthma (15) but also a suppressive effect on the skin test, indicating the response of cutaneous mast cells to antigen is when the mast cells were stimulated with a low concentration of antigen, since DEX reduced not only the intensity of reduced (9) . The findings presented herein provide further support for the notion that levels of mast cell surface FcεRI histamine release response, but also the sensitivity of the cells to antigen challenge. However, it could be reasonably expression may be one of the important therapeutic targets in treating allergic diseases. Although the precise molecular noted that DEX-induced functional modification in mast cells is additionally mediated by other, intracellular mechanisms mechanisms whereby glucocorticoids decrease surface expression of FcεRI on mast cells remain to be determined, (17,30) since DEX-treated mast cells showed a more profound decrease in degranulation than DEX-untreated mast cells with their suppressive effects on surface expression of FcεRI, whether or not it is occupied with IgE, may represent one of almost similar levels of surface-bound IgE (see Fig. 8 ).
Recent results in clinical trials on anti-IgE therapy have the clinically important anti-allergic actions of glucocorticoids. suggested that effects of the treatment on levels of cell
